Sengenics, a leading precision medicine company, today announced that the company has made full-length, correctly folded and functional COVID-19 antigens available for purchase for both research and vaccine development purposes. Sengenics has successfully expressed these antigens using the company’s patented and validated KREX™ technology. ”The surge of COVID-19 infections has pushed us to accelerate the production of SAR
March 13, 2020
· 2 min read